Skip to main content
. 2022 Feb 14;43(9):2397–2409. doi: 10.1038/s41401-022-00862-1

Fig. 6. Temsirolimus exerts more potent tumor growth inhibitory activity in PTEN-deficient tumors than in PTEN-proficient tumors.

Fig. 6

a Size of tumors derived from OS-RC2 cells subcutaneously implanted into nude mice and treated with either vehicle or temsirolimus. The data are presented as the mean ± SD values (n = 10). b Tumors derived from OS-RC2 cells were harvested and weighed on day 15 post treatment. The data are presented as the mean ± SD values (n = 10). Significance was assessed using Mann–Whitney U test. c IHC staining for Ki67 in representative OS-RC2 tumor tissues. Scale bar, 100 μm. The data are presented as the mean ± SD of three tumors (ten independent fields for each tumor). Significance was assessed using Student’s t test. d Size of tumors derived from A498 cells subcutaneously implanted into nude mice and treated with either vehicle or temsirolimus. The data are presented as the mean ± SD values (n = 10). e Tumors derived from A498 cells were harvested and weighed on day 15 post treatment. The data are presented as the mean ± SD values (n = 10). Significance was assessed using Mann–Whitney U test. f IHC staining for Ki67 in representative A498 tumor tissues. Scale bar, 100 μm. The data are presented as the mean ± SD of three tumors (ten independent fields for each tumor). Significance was assessed using Student’s t test.